Stockscreener 앱 받기
19.42
1.60%
-0.308
전일 마감가:
$19.73
열려 있는:
$19.61
하루 거래량:
1.20M
Relative Volume:
0.48
시가총액:
$2.50B
수익:
$715.22M
순이익/손실:
$-250.10M
주가수익비율:
-9.5675
EPS:
-2.03
순현금흐름:
$-205.58M
1주 성능:
-3.02%
1개월 성능:
-20.82%
6개월 성능:
+9.88%
1년 성능:
-33.03%
1일 변동 폭
$19.35
$19.83
1주일 범위
$19.35
$20.70
52주 변동 폭
$16.10
$35.72
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
APLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
19.42 | 2.50B | 715.22M | -250.10M | -205.58M | -2.03 |
|
ARGX
Argen X Se Adr
|
917.15 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
202.50 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.70 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ONC
Beone Medicines Ltd Adr
|
356.02 | 40.27B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
705.05 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
아펠리스 Stock (APLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-06 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-15 | 개시 | Wells Fargo | Overweight |
| 2025-09-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-16 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Neutral |
| 2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-02 | 개시 | Mizuho | Neutral |
| 2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 재확인 | Citigroup | Buy |
| 2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-19 | 개시 | H.C. Wainwright | Buy |
| 2022-06-17 | 재개 | Stifel | Buy |
| 2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
| 2021-09-10 | 재확인 | Credit Suisse | Neutral |
| 2021-09-10 | 재확인 | Needham | Buy |
| 2021-09-10 | 재확인 | Oppenheimer | Outperform |
| 2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-08-19 | 개시 | Jefferies | Buy |
| 2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2020-11-19 | 개시 | Needham | Buy |
| 2020-09-01 | 개시 | Stifel | Buy |
| 2020-07-20 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-04-01 | 개시 | Raymond James | Strong Buy |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
| 2019-12-19 | 개시 | BofA/Merrill | Buy |
| 2019-11-22 | 개시 | Wedbush | Underperform |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
Will Apellis Pharmaceuticals Inc. stock deliver better than expected guidance2025 Market Overview & Low Drawdown Momentum Ideas - newser.com
Risk vs reward if holding onto Apellis Pharmaceuticals Inc.2025 Top Gainers & Stepwise Trade Signal Implementation - newser.com
Why Apellis Pharmaceuticals Inc. (1JK) stock stays on buy listsWeekly Investment Recap & Fast Exit and Entry Strategy Plans - newser.com
Published on: 2025-11-19 03:53:39 - newser.com
Can Apellis Pharmaceuticals Inc. stock resist sector downturnsMarket Weekly Review & AI Driven Price Predictions - newser.com
Can Apellis Pharmaceuticals Inc. stock beat analyst upgradesMarket Activity Report & Safe Capital Allocation Plans - newser.com
Using AI based signals to follow Apellis Pharmaceuticals Inc.Market Sentiment Report & Free Technical Confirmation Trade Alerts - newser.com
Will Apellis Pharmaceuticals Inc. see short term momentum2025 Market Overview & AI Forecast for Swing Trade Picks - newser.com
Apellis Pharma general counsel Watson sells $100k in stock By Investing.com - Investing.com Canada
Apellis Pharma general counsel Watson sells $100k in stock - Investing.com
Why Apellis Pharmaceuticals Inc. (1JK) stock could rally strongly2025 Bull vs Bear & Smart Money Movement Alerts - newser.com
Why Apellis Pharmaceuticals Inc. stock is rated strong buyJuly 2025 Opening Moves & Technical Pattern Alert System - newser.com
Apellis Pharmaceuticals (BIT:1APLS) Price Target Decreased by 10.35% to 30.35 - Nasdaq
How Apellis Pharmaceuticals Inc. stock performs in weak economy2025 Growth vs Value & Fast Exit and Entry Strategy Plans - newser.com
What high frequency data says about Apellis Pharmaceuticals Inc.2025 Earnings Impact & Weekly High Momentum Picks - newser.com
Will breakout in Apellis Pharmaceuticals Inc. lead to full recovery2025 Short Interest & Real-Time Volume Triggers - newser.com
(APLS) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
How to build a dashboard for Apellis Pharmaceuticals Inc. stockVolume Spike & Free Daily Entry Point Trade Alerts - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic valueJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
Will Apellis Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Volume & Fast Gaining Stock Reports - newser.com
Apellis Pharmaceuticals Inc. stock prediction for this weekJuly 2025 Technicals & Expert Curated Trade Setup Alerts - newser.com
How interest rate cuts could boost Apellis Pharmaceuticals Inc. stockJuly 2025 Outlook & Stepwise Entry/Exit Trade Alerts - newser.com
Published on: 2025-11-14 10:40:48 - newser.com
Published on: 2025-11-13 18:42:44 - newser.com
Regression analysis insights on Apellis Pharmaceuticals Inc. performanceTreasury Yields & AI Forecasted Stock Moves - newser.com
Can Apellis Pharmaceuticals Inc. stock sustain market leadershipQuarterly Growth Report & High Accuracy Buy Signal Tips - newser.com
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years - BioSpace
Is Five-Year SYFOVRE Data Shifting the Investment Case for Apellis Pharmaceuticals (APLS)? - Yahoo Finance
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.01%
1.36%
자본화:
|
볼륨(24시간):